Answers are grounded in this paper and cite their sources.
Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.
No takes yet. Share an insight, caveat, or question.
Simeone et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: